Translational Development Acquisition (TDACU) Stock Price, News & Analysis

Company Overview

Translational Development Acquisition Corp. is a Delaware‐incorporated special purpose acquisition company whose units trade on the Nasdaq under the ticker TDACU. As a blank check vehicle, the company was formed to raise capital through an initial public offering for the purpose of identifying, acquiring, or merging with one or more businesses, with a primary focus on the life sciences and biotechnology sectors. By targeting companies at or near pivotal stages of clinical development, Translational Development Acquisition aims to facilitate the translation of promising therapies from the laboratory to the market.

The company’s units consist of one Class A ordinary share and a fraction of a redeemable warrant, offering investors a bundled equity and optional upside participation in the event of a successful merger. Following its IPO, the SPAC holds its trust account funds while management conducts due diligence on potential targets. Once a suitable business combination is announced, shareholders have the option to vote on and redeem their public shares for a pro rata portion of the trust account.

Although Translational Development Acquisition has not yet disclosed a consummated business combination, it leverages a management team and board that draw upon extensive experience in drug development, regulatory affairs, and capital markets. The company seeks to partner with therapeutic innovators based in North America, Europe, and other key global life sciences hubs. By combining private‐company operational expertise with access to public markets, Translational Development Acquisition aims to support the growth and advancement of emerging biopharmaceutical enterprises.

Key Stats

• Today's Range: $10.40 to $10.41
• 50-Day Range: $10.35 to $10.52
• 52-Week Range: $10.00 to $10.72
• Volume: 1,600 shs
• Average Volume: 18,281 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TDACU Stock Analysis - Frequently Asked Questions

How have TDACU shares performed this year?

Translational Development Acquisition's stock was trading at $10.02 at the beginning of the year. Since then, TDACU shares have increased by 3.8% and is now trading at $10.40.

When did Translational Development Acquisition IPO?

Translational Development Acquisition (TDACU) raised $150 million in an initial public offering (IPO) on the week of December 23rd 2024. The company issued 15,000,000 shares at $10.00 per share.

Who are Translational Development Acquisition's major shareholders?

Top institutional investors of Translational Development Acquisition include Alberta Investment Management Corp.

How do I buy shares of Translational Development Acquisition?

Shares of TDACU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance
• Industry: Investment Offices
• Sub-Industry: Trading
• Current Symbol: NASDAQ:TDACU
• CIK: 1926599
• Web: N/A
• Phone: (413) 204-2769
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A